Organs on Chips: The Future of Translational Research
|
|
- Rudolph Palmer
- 6 years ago
- Views:
Transcription
1 Organs on Chips: The Future of Translational Research KRISTIN FABRE, PHD SCIENTIFIC PROGRAM MANAGER NIH NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCE (NCATS) 1
2 Advancing regulatory sciences Drug Failure Modes Why drugs fail human trials Human toxicities found in animals Liver Heart Blood Immune Kidney Lost in translation Regulatory decisions about science are outdated 2D cell-culture often does NOT translate to in vivo systems Animal models are not reliable different physiology 2
3 Poor translational research models Seok; PNAS 2013 NCATS Mission To catalyze the generation of innovative methods and technologies that will enhance the development, testing and implementation of diagnostics and therapeutics across a wide range of human diseases and conditions. 3
4 Microphysiological systems (Organs on chips A five-year program (co-operative agreement) involving partnerships of NIH with DARPA and FDA Goal of achieving 10-organ system mimetic that is physiologically relevant ( human on-a-chip ) Useful for drug pre-clinical safety and toxicology drug-screening Representation of human disease and clinical conditions for POC and efficacy studies Sufficient alternative for animal-testing Genetically diverse conceivable for use in clinical trials setting Advancing regulatory science DARPA Microphysiological Systems Program BAA Microphysiological Systems NIH NCATS Microphysiological Systems Program RFA-RM Integrated Microphysiological Systems for Drug Efficacy and Toxicity Testing in Human Health and Disease (UH2/UH3) RFA-RM Stem/Progenitor Cell-Derived Human Microorgans and -tissues (U18) FDA Advice and expertise to NIH and DARPA NIH-FDA collaboration FDA-DARPA sponsored workshops/collaborations NIH-DARPA Partnership Respective programs independently managed and funded by each Agency PI meetings on consecutive days at the same location Performers (awardees) expected to attend both meetings DARPA and NIH have their own processes for evaluating performer/awardee progress DARPA performers asked to provide access to platform/collaborate with NIH awardees 4
5 MPS platforms Characterization of MPS Platforms Tissues supported Platform assembled off the shelf or fabricated in house Platform description scale Connectivity interface between platforms Chemical environment Cell sources used Functional Assays Reference drug and data sets for testing Microphysiological Systems Availability of compound Dosing paradigm Cellular vs organ toxicity Data on human toxicity Toxicity readouts MPS cell sources Can you standardize a set of criteria for each organ system? For each tissue/organ system there is a need to: Define the starting point primary tissue know key information about sex, ethnicity, age, control or disease related phenotypes Develop a standard of functional characteristics (minimum set of) Develop a standard for molecular and cellular characterization (minimum set of) Working Group Leads for tissue/organ standards Donna Stolz Joan Nichols Steve George Rocky Jonathon Himmelfarb Karen Hirschi John Lynch Angela Christiano Liver Lung Cardiac Bone and Cartilage Kidney Vascular Intestine Skin 5
6 Human on a chip Human-on-a-Chip In vivo Correlation Absorption Distribution Metabolism Excretion Conc(t) Effect(t) Toxicity(t) Rare toxicities Read outs Human biology Tissue/organ structure Cell histology Cell viability Mechanical properties Electrical properties Signaling pathways Cell metabolism Protein synthesis Gene expression Enzyme activities Ion channel properties 6
7 BIG Science: it takes a VILLAGE!! 15+ NIH institutes or centers 30+ NIH IC representatives NIH Common Fund FDA DARPA Pharma 25+ universities/medical research centers Program Directors: Danilo Tagle and Marg Sutherland Thank you! Kristin Fabre fabrek@mail.nih.gov 7
8 U18 generated cell resources UH2 generated organ systems 24 months UH3 phase: -Incorporation of differentiated stem- and progenitor-derived cells -Integration of various organ systems Multicellular architecture Vascularization, innervation, hormonal, humoraland immunological signaling Genetic diversity and pharmacogenomic capacity Representation of normal and disease phenotypes 60 months Integration & validation Base period Period 1 Period 2 DARPA bioengineering Platform + 2 systems 4 systems 7 systems 10 systems Cell viability for 4 weeks Integrated system predicts human in vivo efficacy, toxicity, and pharmacokinetics: o safe and effective o safe and ineffective o unsafe, but effective o unsafe and ineffective Period 3 National Center for Advancing Translational Sciences (NCATS) Fundamental science unprecedentedly advanced, but: Poor transition of those advances to interventions that tangibly improve human health Drug/device development system in crisis Clinical trials system in crisis Poor adoption of demonstrably useful interventions 8
9 Catalyzing Collaborations Within NIH NCI NHLBI NIAID OD NIDCR NEI NIA NLM CC NIDDK NIAMS NIDA FIC NHGRI NICHD NCATS NIEHS CIT NIBIB CSR NIAAA NIDCD NINDS NIMH NCCAM NINR NIGMS NIMHD Catalyzing Collaborations Outside NIH Biotech Pharma Academia NCATS FDA/DARPAA Advocacy Groups Non- Profits Complements does not compete with the work of others Revolutionizes the process of translation by promoting innovative research Galvanizes and supports new partnerships Supports and augments regulatory science and its application Expands the precompetitive space 9
10 NIH NCATS/DARPA/FDA partnerships Memorandum of Understanding (MOU) NIH and DARPA will independently manage and fund separate programs that will be highly coordinated across the two agencies FDA provides regulatory and toxicology expertise Program coordination o Sharing of scientific expertise, materials, resources o Jointly held semi-annual meetings o Development of a common set of validation compounds o Facilitation of collaborations Cellular readouts of the Organs on Chips Genomics, proteomics Biochemical and physiological analysis ph, O2, MEA Metabolomics Optogenetics Inflammatory responses Functional analyses 10
11 Poor translational research models Seok; PNAS
Lili M. Portilla, MPA Acting Director, Office of Policy, Communications and Strategic Alliances National Center for Advancing Translational Sciences
Lili M. Portilla, MPA Acting Director, Office of Policy, Communications and Strategic Alliances National Center for Advancing Translational Sciences (NCATS), NIH GUIRR Meeting, October 9, 2012 Established
More informationChristopher P. Austin, M.D. Director, NCATS IOM CTSA Review Committee January 24, 2013
Christopher P. Austin, M.D. Director, NCATS IOM CTSA Review Committee January 24, 2013 Basic Laboratory Research Clinical Research Improved Public Health Translational Research Population Research Basic
More informationDr. Krishna Balki Balakrishnan Senior Technology Manager, Office of Strategic Alliances National Center for Advancing Translational Sciences, NIH
Dr. Krishna Balki Balakrishnan Senior Technology Manager, Office of Strategic Alliances National Center for Advancing Translational Sciences, NIH Email: Balki@nih.gov Established on December 23, 2011 Part
More informationBringing Medical Devices for Cancer to the Marketplace: 2014 Overview of the NCI Small Business Programs
Bringing Medical Devices for Cancer to the Marketplace: 2014 Overview of the NCI Small Business Programs A Greg Evans, PhD Team Leader Cancer Imaging/Biology/Control NCI SBIR Development Center Monday
More informationLili M. Portilla, MPA Acting Director, Office of Policy, Communications and Strategic Alliances National Center for Advancing Translational Sciences
Lili M. Portilla, MPA Acting Director, Office of Policy, Communications and Strategic Alliances National Center for Advancing Translational Sciences (NCATS), NIH Email: Lili.Portilla@nih.gov Established
More informationRare Diseases: Challenges and Opportunities NIH Perspective
Rare Diseases: Challenges and Opportunities NIH Perspective Stephen C. Groft, Pharm.D. Office of Rare Diseases Research (ORDR) National Center for Advancing Translational Science (NCATS) National Institutes
More informationNon-Dilutive Funding For Clinical Stage R&D
FreeMindGroup FreeMind Group @FreeMindGrp Non-Dilutive Funding For Clinical Stage R&D Meytal Waiss Director, Business Development FreeMind Group The Global Non-Dilutive Funding Leader FreeMind Group, LLC
More informationList of Acronyms. National Institutes of Health Offices, Institutes, and Centers
List of Acronyms National Institutes of Health Offices, Institutes, and Centers Offices: OD Office of the Director Institutes: NCI NEI NHGRI NHLBI NIA NIAAA NIAID NIAMS NIBIB NICHD NIDA NIDCD NIDCR NIDDK
More informationTechnology Development Funding Program Round 3
Technology Development Funding Program Round 3 CWRU January 26, 2015 1 Program Overview NIH Center for Accelerated Innovations (NCAI) at Cleveland Clinic Mission to improve translation of basic science
More informationExpedited Reporting. Darlene Kitterman, MBA Director, Investigator Support & Integration Services, OCTRI September 25, 2014
Expedited Reporting Darlene Kitterman, MBA Director, Investigator Support & Integration Services, OCTRI September 25, 2014 Journal of Clinical Research Best Practices Vol. 7, No. 1, January 2011 Can You
More informationCritical Path Initiative: An Update
Critical Path Initiative: An Update Raymond Woosley, MD, PhD President and CEO, Critical Path Institute Presented at: FIRST ANNUAL PATIENT-REPORTED OUTCOMES (PRO) CONSORTIUM WORKSHOP March 23, 2010 Bethesda,
More informationSMALL BUSINESS INNOVATION RESEARCH (SBIR) SMALL BUSINESS TECHNOLOGY TRANSFER (STTR) GRANT APPLICATIONS
U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES PHS 2018-2 OMNIBUS SOLICITATION OF THE NATIONAL INSTITUTES OF HEALTH, CENTERS FOR DISEASE CONTROL AND PREVENTION, AND FOOD AND DRUG ADMINISTRATION FOR SMALL
More informationThe National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) as a source of Non-Dilutive Funding
@FreeMindGrp FreeMind Group The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) as a source of Non-Dilutive Funding FreeMind Group Webinar Jonathan Adalist FreeMind Group, LLC
More informationWhat is the Future of NIH funded Clinical Research in IBD?
IBD Clinical Trials Workshop What is the Future of NIH funded Clinical Research in IBD? Stephen P. James, M.D. January 13-14, 2017 Future? FY 2015 NIH Awards for IBD related research 338 Awards $128 Million
More informationContent Areas of the Pharmacy Curriculum Outcomes Assessment (PCOA )
Content Areas of the Pharmacy Curriculum Outcomes Assessment (PCOA ) Area 1.0 Basic Biomedical Sciences (10%) Area 2.0 Pharmaceutical Sciences (33%) Area 3.0 Social/Behavioral/Administrative Sciences (22%)
More informationIndustry Academic Collaboration: A Key to Successful Involvement of Patients Early in Clinical Development
Industry Academic Collaboration: A Key to Successful Involvement of Patients Early in Clinical Development Aernout van Haarst PhD Director, European Corporate Development Feb 2016 Industry Academic Collaboration
More informationThe Integrated Biomedical Sciences Graduate Program
The Integrated Biomedical Sciences Graduate Program at the university of notre dame Cutting-edge biomedical research and training that transcends traditional departmental and disciplinary boundaries to
More informationMaximizing opportunities towards achieving clinical success D R U G D I S C O V E R Y. Report Price Publication date
F o r a c l e a r e r m a r k e t p e r s p e c t i v e Early Stage Drug Safety Strategies & Risk Management Maximizing opportunities towards achieving clinical success D R U G D I S C O V E R Y Report
More informationCollaborative Rare Diseases Research Activities at NIH
Collaborative Rare Diseases Research Activities at NIH Christopher P. Austin, M.D. Director National Center for Advancing Translational Sciences IRDiRC April 16, 2013 Background ~ 18 25 million people
More informationPresentation to the Committee on Accelerating Rare Disease Research and Orphan Product Development
Presentation to the Committee on Accelerating Rare Disease Research and Orphan Product Development 23 November 2009 Sharon F. Terry, MA President & CEO, Genetic Alliance Executive Director, PXE International
More informationRequest for Projects for Wake Forest Brain Tumor SPORE Application
1 Request for Projects for Wake Forest Brain Tumor SPORE Application This RFA is for three types of projects that will be taken into consideration for inclusion in the Wake Forest Brain Tumor Specialized
More informationNIH/NIAID Radiation/Nuclear Medical Countermeasures Development Program
NIH/NIAID Radiation/Nuclear Medical Countermeasures Development Program Bert W. Maidment, Ph.D. Associate Director for Product Development Division of Allergy, Immunology, and Transplantation National
More informationStrategies for Assessment of Immunotoxicology in Preclinical Drug Development
Strategies for Assessment of Immunotoxicology in Preclinical Drug Development Rebecca Brunette, PhD Scientist, Analytical Biology SNBL USA Preclinical Immunotoxicology The study of evaluating adverse effects
More informationDes cellules-souches dans le poumon : pourquoi faire?
Des cellules-souches dans le poumon : pourquoi faire? Karl-Heinz Krause Dept. of Pathology and Immunology, Medical Faculty Dept. of Genetic and Laboratory Medicine, University Hospitals Geneva, Switzerland
More informationPredicting Tissue Distribution & Clearance of Antibody Formats to Improve Selectivity of Targeted Therapies
Predicting Tissue Distribution & Clearance of Antibody Formats to Improve Selectivity of Targeted Therapies Ben-Fillippo Krippendorff, Roche Innovation Center Basel ben-fillippo.krippendorff@roche.com
More informationThe Impact of National Institutes of Health Funding on U.S. Cardiovascular Disease Research
The Impact of National Institutes of Health Funding on U.S. Cardiovascular Disease Research Radmila Lyubarova 1, Brandon K. Itagaki 2,3, Michael W. Itagaki 4 * 1 Division of Cardiology, Department of Medicine,
More informationDrug Development: Why Does it Cost so Much? Lewis J. Smith, MD Professor of Medicine Director, Center for Clinical Research Associate VP for Research
Drug Development: Why Does it Cost so Much? Lewis J. Smith, MD Professor of Medicine Director, Center for Clinical Research Associate VP for Research Drug Development Process by which new chemical entities
More informationThe Road to Functional Bioanalysis: Development and Validation of a Cell-Based Assay for Neutralizing Anti-Drug Antibody Analysis
The Road to Functional Bioanalysis: Development and Validation of a Cell-Based Assay for Neutralizing Anti-Drug Antibody Analysis Christelle Pythoud, PhD 2 nd EBF YSS, Barcelona Spain Celerion Switzerland
More informationNIH Funding for Novel Biomaterials Technologies
NIH Funding for Novel Biomaterials Technologies David Rampulla Program Director Biomaterials Delivery Systems for Drugs and Biologics Synthetic Biology for Technology Development NIBIB/NIH 301-451-4774
More informationQuantitative And Spatial Optimization Of Therapeutic Fusion Proteins
Quantitative And Spatial Optimization Of Therapeutic Fusion Proteins Jeffrey Way, Ph.D. Senior Staff Scientist, Wyss Institute, HMS CEO, General Biologics, Inc. 1 Chimeric Activators Drug design and targeted
More informationThe Role of a Clinical Statistician in Drug Development By: Jackie Reisner
The Role of a Clinical Statistician in Drug Development By: Jackie Reisner Types of studies within clinical development Phase I Phase II Phase III Phase IV Phase I First Human Dose (FHD) Young healthy
More informationNCI Research Networks Model for Collaboration with Bioelectronics Round Table
NCI Research Networks Model for Collaboration with Bioelectronics Round Table Larry Clarke, Cancer Imaging Program DCDT, NCI Detail: NIBIB Guest Scientist: NIST 1 Bioelectronics Round Table Research Triangle
More informationNCI SBIR & STTR Funding, mentoring & networking assistance for next-generation life science technologies
NCI SBIR & STTR Funding, mentoring & networking assistance for next-generation life science technologies Oct 12, 2016 Amir Rahbar, PhD, MBA Program Director National Cancer Institute SBIR Development Center
More informationTECHNOLOGIES & SERVICES FOR THERAPEUTIC ANTIBODY DEVELOPMENT
Specialist in tissue analysis by Histology, Immunohistochemistry and In Situ Hybridization TECHNOLOGIES & SERVICES FOR THERAPEUTIC ANTIBODY DEVELOPMENT CONTENTS Histalim: who we are Our areas of expertise
More informationREIMAGINING DRUG DEVELOPMENT:
Biology Reconstructed REIMAGINING DRUG DEVELOPMENT: Accurate Disease Modeling To Drive Successful Therapies Julia Kirshner, CEO julia@zpredicta.com 1 SUCCESS RATES OF DRUG DEVELOPMENT ARE LOW, " PARTICULARLY
More informationGraduate Courses: Advanced Pharmaceutics Prerequisites: Course No: Instructor: Credits: Description:
The following is a listing of courses offered by the Graduate Program in Pharmaceutical Science. Prerequisites and brief descriptions are included for each course. For more information on a particular
More informationBeth Hutchins, PhD PhRMA ICH Gene Therapy Discussion Group
ICH Considerations on General Principles to Address the Risk of Inadvertent Germline Integration of Gene Therapy Vectors and Current Topics on Gene Therapy in USA Beth Hutchins, PhD PhRMA ICH Gene Therapy
More informationEuropean Induced Pluripotent Stem Cell Bank
European Induced Pluripotent Stem Cell Bank Background Researchers are looking for ways to validate pathways using human data. ips cells are one approach to this. ips research and banking is fragmented
More informationThe Role of Adult Stem Cells in Personalized and Regenerative Medicine
The Role of Adult Stem Cells in Personalized and Regenerative Medicine Christopher J. Neill, Director of Corporate Operations American CryoStem Corporation Objective To illustrate the potential benefits
More informationNeuroscience at NIH. NINDS, NIMH, NIDA, NIA, NICHD, NEI, NIDCD, NIAAA Each has its own disease mission All fund basic science
Neuroscience at NIH NIH s mission is to seek fundamental knowledge about the nature and behavior of living systems and the application of that knowledge to enhance health, lengthen life, and reduce the
More informationThe 3Rs: are Human Stem Cells and Organs on Chip alternatives?
The 3Rs: are Human Stem Cells and Organs on Chip alternatives? Towards precision medicine in future healthcare Christine Mummery Leiden University Medical Centre University Twente hdmt Three kinds of human
More informationMain Content Domain % of Operational Items # of Operational Items
The PCOA content areas and subtopics for the 2016-2017 administration are based upon the outcomes from the US College of Pharmacy Curricula Survey. The assessment is composed of four content areas that
More informationleading the way in research & development
leading the way in research & development people. passion. possibilities. ABBVIE 2 immunology AbbVie Immunology has a demonstrated record of success in identifying and developing both small molecule and
More informationHorizon 2020 funding opportunities for Regenerative Medicine ( ) Rudolf Fryček, PhD.
Horizon 2020 funding opportunities for Regenerative Medicine (2018-2020) Rudolf Fryček, PhD. Disclaimer: Any information mentioned is preliminary only, always consult the official documents. 1 Outline
More informationUniversity of Pennsylvania Perelman School of Medicine High Throughput Screening Core
University of Pennsylvania Perelman School of Medicine High Throughput Screening Core Sara Cherry, Ph. D. David C. Schultz, Ph. D. dschultz@mail.med.upenn.edu (215) 573 9641 67 John Morgan Building Mission
More information"Stratification biomarkers in personalised medicine"
1/12 2/12 SUMMARY REPORT "Stratification biomarkers in personalised medicine" Workshop to clarify the scope for stratification biomarkers and to identify bottlenecks in the discovery and the use of such
More informationICH Topic E16 Genomic Biomarkers Related to Drug Response: Context, Structure and Format of Qualification Submissions. Step 3
European Medicines Agency June 2009 EMEA/CHMP/ICH/380636/2009 ICH Topic E16 Genomic Biomarkers Related to Drug Response: Context, Structure and Format of Qualification Submissions Step 3 NOTE FOR GUIDANCE
More informationM252 M262 Course Syllabus M252A-B & M262A-B. Molecular Mechanisms of Human Diseases. Course Director: Professor Yibin Wang
M252A-B & M262A-B Molecular Mechanisms of Human Diseases Course Director: Professor Yibin Wang (yibinwang@mednet.ucla.edu) Course Coordinator: Yesenia Rayos yrayos@lifesci.ucla.edu Proposal Coordinator:
More informationOptimisation de votre programme de développement
Optimisation de votre programme de développement Cedric Lamy, PhD. Cedric.lamy@crl.com Charles River Overview 65-year history: Founded in 1946, publicly traded (NYSE:CRL) Investment in skilled staff: ~7,500
More informationProduction Assistance for Cellular Therapies PACT
Production Assistance for Cellular Therapies PACT Traci Heath Mondoro, PhD NHLBI Bethesda, Maryland Renewed PACT Program Renewed January 15, 2010 Scope and size expanded Cell Processing Facilities (CPFs)
More informationThe Five Key Elements of a Successful Metabolomics Study
The Five Key Elements of a Successful Metabolomics Study Metabolomics: Completing the Biological Picture Metabolomics is offering new insights into systems biology, empowering biomarker discovery, and
More informationBiological Warfare Defense at DARPA Program Overview
Biological Warfare Defense at DARPA Program Overview Stephen S. Morse, Ph.D. DARPA/ smorse@darpa.mil DARPA BWD Program (including novel or bioengineered pathogens) DARPA BWD Program (most current techniques
More informationDetermining the Predictive Validity of 3D Models & Achieving Standardization for Preclinical Efficacy Testing
Determining the Predictive Validity of 3D Models & Achieving Standardization for Preclinical Efficacy Testing August 28 2017 Jason Ekert, Head of Complex In Vitro Models Platform Technology and Sciences
More informationDr Amy Prosser Careers in Research: Industry
www.rsb.org.uk Dr Amy Prosser Careers in Research: Industry @RoyalSocBio #BiologyWeek #RSBcareersDay Careers in Research: Working in the Pharma Industry Dr Amy Prosser My Career History 2011 Completed
More informationAlliance for Regenerative Medicine
Alliance for Regenerative Medicine Michael Werner Executive Director Alliance for Regenerative Medicine ARM s Focus & Role As the leading global advocate for the regenerative medicine and advanced therapies
More informationFDA Oversight of Gene Therapy
FDA Oversight of Gene Therapy Celia M. Witten, Ph.D., M.D. Deputy Director, FDA CBER Rare Disease and Orphan Products Breakthrough Summit NORD October 17, 2016 Hyatt Regency Crystal City Crystal City,
More informationA gateway to academic excellence for Biotech and Pharma
A gateway to academic excellence for Biotech and Pharma 6 8 12 Connecting meaningful endpoints: Ksilink s comprehensive translational effort Ksilink s patient centered, translational technology Engaging
More informationThe room was more than 3/4 full with greater than 150 people in attendance.
Summary The room was more than 3/4 full with greater than 150 people in attendance. The questions were well distributed across all four panelists. All the Panelists were very interactive and were able
More informationSSPPS STRATEGIC PLAN. Pharmacy Education, Pharmaceutical Sciences Research, Clinical Pharmacy Practice. April 30, Overview
SSPPS STRATEGIC PLAN Pharmacy Education, Pharmaceutical Sciences Research, Clinical Pharmacy Practice April 30, 2012 Overview Here we present the 2012-2017 strategic plan for the Skaggs School of Pharmacy
More informationFood and Drug Administration (FDA) 101
Food and Drug Administration (FDA) 101 What is the Food and Drug Administration (FDA)? The FDA is an agency within the U.S. Department of Health and Human Services that is responsible for protecting the
More informationBSc BIOMEDICAL SCIENCE
Overview College of Science Biomedical Science Core March 2017 (1) BSc BIOMEDICAL SCIENCE Biomedical Science Degree 2015 1 College of Science, NUI Galway Fullscreen Next page Overview [60 credits] [60
More informationPACT. PACT Program. Production Assistance for Cellular Therapies
PACT Production Assistance for Cellular Therapies University of Wisconsin PACT-sponsored Workshop Developing Cellular Therapies: From Preclinical Safety To Clinical Evaluation Tuesday, April 09, 2013 Robert
More informationATIP Avenir Program 2018 Young group leader
ATIP Avenir Program 2018 Young group leader Important dates - October 17th (4 pm) 2017 : opening of the registrations online - November 23 th 2017: deadline for the online submission, the mailing of the
More informationPHARMACOLOGY. Dr Paul Spiers, Dept of Pharmacology & Therapeutics Tel ,
PHARMACOLOGY COURSE COORDINATOR: Dr Paul Spiers, Dept of Pharmacology & Therapeutics Tel 896 2146, spiersj@tcd.ie ECTS Value 10 Credits Contact Hours 46 hrs lectures 2 tutorials 3 hr 2 computer sessions
More informationLecture 23: Clinical and Biomedical Applications of Proteomics; Proteomics Industry
Lecture 23: Clinical and Biomedical Applications of Proteomics; Proteomics Industry Clinical proteomics is the application of proteomic approach to the field of medicine. Proteome of an organism changes
More informationPartnership to accelerate novel treatments for heart valve disease
Partnership to accelerate novel treatments for heart valve disease Mayo Clinic, NIH/NCATS, Sanofi, University of Minnesota, Nanosyn Jordan D. Miller, PhD Innovator Presentation Tweet With Us Jordan D.
More informationNON-ANIMAL APPROACHES TO SAFETY ASSESSMENT OF COSMETIC PRODUCTS. Cutting-Edge Science and Constant Innovation: The Keys to Success
NON-ANIMAL APPROACHES TO SAFETY ASSESSMENT OF COSMETIC PRODUCTS Cutting-Edge Science and Constant Innovation: The Keys to Success 2 NON-ANIMAL APPROACHES TO SAFETY ASSESSMENT OF COSMETIC PRODUCTS Cutting-Edge
More informationStem Cell Services. Driving Innovation for Stem Cell Researchers
Driving Innovation for Stem Cell Researchers Stem Cell Services Partner with us and have access to the most advanced and comprehensive stem cell services available today. 675 W. Kendall St. Cambridge,
More informationThe Two-Hybrid System
Encyclopedic Reference of Genomics and Proteomics in Molecular Medicine The Two-Hybrid System Carolina Vollert & Peter Uetz Institut für Genetik Forschungszentrum Karlsruhe PO Box 3640 D-76021 Karlsruhe
More informationAN INTERNATIONAL COALITION ADVANCING A NEW PARADIGM FOR CHEMICAL SAFETY TESTING
AN INTERNATIONAL COALITION ADVANCING A NEW PARADIGM FOR CHEMICAL SAFETY TESTING READING REFERENCE: 1. Krewski D. 2010. Toxicity testing in the 21st century: a vision and a strategy. J Toxicol Environ Health
More informationA unique Collaborative Model for the Discovery of New Therapeutic Approaches
A unique Collaborative Model for the Discovery of New Therapeutic Approaches THE INNOVATION GAP OPEN INNOVATION TO ADDRESS THE LACK OF PRODUCTIVITY OF BIOPHARMACEUTICAL RESEARCH A PRE-COMPETITIVE PHARMA
More informationresearch opportunities newsletter Alcohol, Drugs or Abuse &/or Smoking Bioimaging and Radiation Research Complementary & Alternative Medicine (CAM)
Funding research opportunities newsletter Announcements Alcohol, Drugs or Abuse &/or Smoking Bioimaging and Radiation Research Bioinformatics Biomedical Technology Cancer & Blood Complementary & Alternative
More informationOverview of Biologics Testing and Evaluation: Regulatory Requirements and Expectations. Audrey Chang, PhD, Senior Director Development Services
Overview of Biologics Testing and Evaluation: Regulatory Requirements and Expectations Audrey Chang, PhD, Senior Director Development Services Definition of Biologics: PHS Act, section 351 Virus, therapeutic
More informationIN VITRO TOXICITY TESTING: TECHNOLOGIES AND GLOBAL MARKETS
IN VITRO TOXICITY TESTING: TECHNOLOGIES AND GLOBAL MARKETS PHM017E January 2014 Robert Hunter Project Analyst ISBN: 1-56965-661-4 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA 866-285-7215
More informationGoals of pharmacogenomics
Goals of pharmacogenomics Use drugs better and use better drugs! People inherit/exhibit differences in drug: Absorption Metabolism and degradation of the drug Transport of drug to the target molecule Excretion
More informationCDISC Controlled Terminology across the Clinical Trial Continuum. Bay Area Implementation Network 6 March 2008
CDISC Controlled Terminology across the Clinical Trial Continuum Bay Area Implementation Network 6 March 2008 Bron Kisler Co-Founder / Director of Terminology CDISC Terminology Initiative Overview / Background
More informationEarly Phase Education WHITEPAPER. Three major items to consider when moving from preclinical to clinical development
Early Phase Education WHITEPAPER Three major items to consider when moving from preclinical to clinical development Three major items to consider when moving from preclinical to clinical development Dr.
More informationTHE IMPACT OF THE AFFORDABLE CARE ACT (ACA) ON CANCER RESEARCH, CARE, AND PREVENTION
THE IMPACT OF THE AFFORDABLE CARE ACT (ACA) ON CANCER RESEARCH, CARE, AND PREVENTION William S. Dalton, PhD, MD AACR April 17, 2016 Designing a Federated Model To Support Research & Healthcare Offices
More informationDelivering on the promise: the clinical application of new diagnoses and treatments for RD K A T E B U S H B Y N E W C A S T L E U N I V E R S I T Y
Delivering on the promise: the clinical application of new diagnoses and treatments for RD K A T E B U S H B Y N E W C A S T L E U N I V E R S I T Y PERSPECTIVE/ DISCLAIMERS Doctor with >24 years experience
More informationIntroduction to Assay Development
Introduction to Assay Development A poorly designed assay can derail a drug discovery program before it gets off the ground. While traditional bench-top assays are suitable for basic research and target
More informationApplication of RNA Interference to Anti-Doping. Matthew Fedoruk, Ph.D. Gene & Cell Doping Symposium 2013, Beijing, China
Application of RNA Interference to Anti-Doping Matthew Fedoruk, Ph.D. Gene & Cell Doping Symposium 2013, Beijing, China From Plants to Worms to Humans: Discovery and Mechanism of RNAi Alnylam Pharmaceuticals
More informationSupporting information. Single-cell and subcellular pharmacokinetic imaging allows insight into drug action in vivo
Supporting information Single-cell and subcellular pharmacokinetic imaging allows insight into drug action in vivo Greg Thurber 1, Katy Yang 1, Thomas Reiner 1, Rainer Kohler 1, Peter Sorger 2, Tim Mitchison
More informationBSc Biomedical Science Degree
BSc Biomedical Science Degree Overview...2 BSc Biomedical Science...3 BSc Biomedical Science Pathway...4 BSc Biomedical Science Biochemistry Pathway...5 BSc Biomedical Science Pathway...6 BSc Biomedical
More informationBIOMEDICAL ENGINEERING (BMED)
Biomedical Engineering (BMED) 1 BIOMEDICAL ENGINEERING (BMED) BMED 1000. Introduction to Biomedical Engineering. 1 Credit Hour. An introduction to the field of biomedical engineering, with an emphasis
More informationFrom Molecules To Medicine
From Molecules To Medicine A journey through research and development From Molecules To Medicine Bayer invests considerable resources in the research and development of new drugs, with the aim of improving
More informationS3 Table. Research topics in molecular biology.
S3 Table. Research topics in molecular biology. B0 cell express activ signal develop Development, Molecular and Cellular Biology, Cancer Research, Genes & Development, Journal of Immunology B1 patient
More informationPAREXEL GENOMIC MEDICINE SERVICES. Applying genomics to enhance your drug development journey
PAREXEL GENOMIC MEDICINE SERVICES Applying genomics to enhance your drug development journey YOUR JOURNEY. OUR MISSION. Genomic expertise to simplify the route to product approval and maximize patient
More informationTuberculosis Drug Accelerator
Tuberculosis Drug Accelerator Overview of Activities and Portfolio who, why, what, how, by when and where are we now Steve Berthel 1 What is the Tuberculosis Drug Accelerator? The A is a groundbreaking
More informationInnovative Pharmaceutical Solutions for Discovery Chemistry, Biology and cgmp Manufacturing
Innovative Pharmaceutical Solutions for Discovery Chemistry, Biology and cgmp Manufacturing Overview Serving biotech and pharma community since 1998 Proven track record of advancing small molecules from
More informationMODULE 3 Preclinical safety May 2016 POST-GRADUATE PROGRAMME IN PHARMACEUTICAL MEDICINE & MEDICINES DEVELOPMENT SCIENCES
MODULE 3 Preclinical safety 11-12 May 2016 POST-GRADUATE PROGRAMME IN PHARMACEUTICAL MEDICINE & MEDICINES DEVELOPMENT SCIENCES René VERLOES M.D., Ph.D., lecturer in preclinical safety of medicines VUB,
More informationCOPE. FAQs CORPORATE ONCOLOGY PROGRAM FOR EMPLOYEES
COPE CORPORATE ONCOLOGY PROGRAM FOR EMPLOYEES FAQs This brochure addresses FAQ and is prepared solely for the German market. Local adjustments may be necessary. Please contact us if you require additional
More information"From Bedside to Bench and Back: regulatory requirements for collaborations between pharma industry and academia
"From Bedside to Bench and Back: regulatory requirements for collaborations between pharma industry and academia Damir Hamamdžić D.V.M., Ph.D. Office of Research Regulatory Affairs Rutgers University RWJMS
More informationCENTRAL NERVOUS SYSTEM (CNS) BIOMARKERS: TECHNOLOGIES AND GLOBAL MARKETS
CENTRAL NERVOUS SYSTEM (CNS) : TECHNOLOGIES AND GLOBAL MARKETS BIO074C March 2016 Jackson Highsmith Project Analyst ISBN: 1-62296-246-X BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA 866-285-7215
More informationHuman Genomics, Precision Medicine, and Advancing Human Health. The Human Genome. The Origin of Genomics : 1987
Human Genomics, Precision Medicine, and Advancing Human Health Eric Green, M.D., Ph.D. Director, NHGRI The Human Genome Cells Nucleus Chromosome DNA Human Genome: 3 Billion Bases (letters) The Origin of
More informationCAP Accreditation Checklists 2017 Edition
CAP Accreditation Checklists 2017 Edition The College of American Pathologists (CAP) accreditation checklists contain the CAP accreditation program requirements, developed on more than 50 years of insight
More information8. Clinical Trial Assessment Phase II
8. Clinical Trial Assessment Phase II Junko Sato, PhD Office of New Drug I, PMDA Disclaimer: The information within this presentation is based on the presenter s expertise and experience, and represents
More informationWelcome to R&D Day! Christine Lindenboom VP, Investor Relations & Corporate Communications
Welcome to R&D Day! Christine Lindenboom VP, Investor Relations & Corporate Communications 1 Alnylam Forward Looking Statements This presentation contains forward-looking statements, within the meaning
More information